News
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have
If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today
Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many
Why Sarepta Therapeutics Stock Is Soaring Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were soaring 10.4% higher as of 10:58 a.m. ET on Friday. The big gain came after the biopharmaceutical company announced that the U.S. Food and Drug
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Equity markets can be highly volatile in the short run. Where the S&P 500 might land in the next six months is anyone's guess. However, over a decade, major indexes tend to move steadily in the
2 Magnificent Growth Stocks to Buy With $500
Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic
Why QuidelOrtho Stock Is Crashing Today
Shares of QuidelOrtho (NASDAQ: QDEL) were crashing 31.4% lower as of 11:30 a.m. ET on Wednesday. The huge decline came after the in vitro diagnostics company announced its 2023 full-year and
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
Operator
Source Fool.com
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and
2 Growth Stocks to Buy at a Discount
The stock market is on fire as 2024 kicks off. As a result, many investors might be reviewing their long-term financial goals as well as their plans for stock purchases. As always, it's best to
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's
2 Bargain Basement Stocks to Buy Now and Hold Forever
Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working
Is Vertex Pharmaceuticals Stock a Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are
3 Stocks That Could Trounce the Market in 2024
Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.
Three Motley Fool contributors think
Could Vertex Pharmaceuticals Reach $500 in 2024?
Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2023 Earnings CallFeb 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market